Celgene Corp.

54 trials 13 recruiting Commercial sponsor Merged from 2 name variants

Filter these 54 trials by condition, phase, country and more.

Open in Search →

54 Registered trials

13 Recruiting

40 Completed trials

23 Countries active

73 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 19 Phase II/III: 3 Phase II: 11 Phase I/II: 6 Phase I: 6 Phase I (Other): 9

Oversight events:

23 temporary halts 1 urgent safety measure 5 unexpected events 2 corrective measures across 11 trials

View oversight register →

100%

40 of 40 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 4 Myelofibrosis 3 Marginal zone lymphoma 2 Acute myeloid leukaemia 2 Crohn's disease 2 Myelodysplastic syndrome 2 Systemic lupus erythematosus 2 Multiple sclerosis 2 Primary myelofibrosis 2 Follicular lymphoma 1 Glioblastoma 1 Non-small cell lung cancer 1

Top IMPs

DEXAMETHASONE 7 LUSPATERCEPT 7 MEZIGDOMIDE 7 DARATUMUMAB 5 AZACITIDINE 4 CARFILZOMIB 4 GOLCADOMIDE 4 IDECABTAGENE VICLEUCEL 4 BORTEZOMIB 3 IBERDOMIDE 3 LENALIDOMIDE 3 POMALIDOMIDE 3

All trials — page 3

54 total

A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended

2023-506564-14-00 Phase I 4 countries
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not R… Ended

2023-508727-12-00 Phase II 2 countries DEXAMETHASONE; MEZIGDOMIDE
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a… Ended

2023-509969-20-00 Phase I 2 countries
A clinical trial to evaluate if CC-486 plus pembrolizumab works and is safe in patients with advanced or metastatic non-small cell lung canc… Ended

2024-513405-31-00 Phase II 1 country AZACITIDINE
Study to allow continuation of treatment with Azacitidine for patients with blood disorders who previously participated in a clinical trial … Ended

2023-503272-25-00 Phase II 1 country AZACITIDINE
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended

2023-509472-42-00 Phase III 14 countries ALNUCTAMAB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIU…

Showing 49–54 of 54 trials

← All sponsors A–Z